INTRODUCTION AND OBJECTIVES: Voluntary medical male circumcision (VMMC) has shown to reduce HIV transmission by 60%. The WHO and UNAIDS have recommended that VMMC be made available in 14 sub-Saharan African countries with high HIV prevalence and low male circumcision (MC) rates. Thus, device-assisted MC has been proposed as a method to simplify MC and enable safe task-shifting to non-physician healthcare providers, especially in regions lacking medical resources and trained physicians. The ShangRing (SR) is a WHOprequalified MC device usable across all ages. The integration of topical anesthesia (TA) with SR MC would further simplify the procedure and broaden its appeal. In this randomized clinical trial (RCT), we compared the safety and efficacy of TA vs. injectable anesthesia (IA) with SR MC.
METHODS: 344 males aged 10-54 years were enrolled in a two center RCT in Kenya. Participants were randomized in 2 to 1 fashion to TA using 2.5% lidocaine þ 2.5% prilocaine cream vs. IA using 1% lidocaine. All participants were circumcised using the no-flip SR technique, which involves the insertion of an inner plastic ring under the foreskin followed by secure clamping of an outer ring to provide hemostatic occlusion. The foreskin distal to the device is then excised. Data on pain scores using the Visual Analogue Pain Scale, rate of adverse events (AEs), operative time, and time to complete wound healing were collected.
RESULTS: 226 participants were allocated to TA vs. 118 to IA. All (100%) participants were successfully circumcised. 21 of the 226 participants initially assigned to TA required IA due to inadequate application of TA. Mean pain scores during application of anesthesia was significantly lower (0.02 vs. 1.2, p<0.001) with TA. Mean pain scores during MC were similar (0.2 vs. 0.1, p[0.11) for both groups but lower with TA 20 minutes post-operatively (0.3 vs. 1.6, p<0.001). No AEs were encountered. Mean operative time (5.0 vs. 5.1, p[0.61) and rates of complete wound healing on day 42 post-circumcision were similar (86.0% vs. 87.6%, p[0.80) between the two groups (Table 1) .
CONCLUSIONS: TA was safe and efficacious with SR MC, demonstrating a superior anesthetic effect pre and post-operatively to IA. The use of TA could potentially increase recruitment of patients for MC, which would further the goal of increasing the rate of MC in sub-Saharan Africa.
INTRODUCTION AND OBJECTIVES: Accurately estimating fragment size is an important task during ureteroscopic stone management, as it can provide determination of the adequacy of dusting or the ability to retrieve fragments through a ureteral access sheath. We previously reported an ex vivo validation of a novel software that can accurately measure small stone fragments. This study assesses the feasibility of integrating the software into operating room workflow.
METHODS: Mock stone fragments were selected to mimic a variety of non-ideal fragmentation conditions. Using a commercial model of the kidney and ureter designed for ureteroscopy training, we performed two versions of a timed basketing task to simulate real-time software measurement. In the conventional version, the ureteroscope was navigated from the UPJ to the stone in a superior pole calyx, then the stone was retrieved with the basket back to the UPJ. In the measurement version, the ureteroscope was again navigated from the UPJ to the stone, then real-time measurement of the stone was performed using the software, followed by stone retrieval to the UPJ. Differences in task completion time and fragment characteristics were compared.
RESULTS: A total of 20 stone fragments were selected with different combinations of internal characteristics: size (mean 7.1 mm, range 3.2-10.3 mm), 3-dimensional shape (50% pyramidal, 30% ovoid, 20% cuboid), surface contour (50% smooth, 50% rough), and planar symmetry (60% asymmetric, 40% symmetric). In the conventional version of the task, mean completion time was 16.5 sec (range 10.1-33.6 sec), compared with a mean completion time of 38.8 sec (range 27.2-60.0 sec) in the measurement version. The additional procedure time required to perform real-time measurement averaged 22.2 sec (range 8.8-42.6 sec). Variation in these times for certain stones was typically due to more challenging planar alignment of the ureteroscope and basket tip, which is required for accurate calculation using the software.
CONCLUSIONS: Integrating a novel software for real-time stone measurement during ureteroscopy is feasible and has a modest effect on the time required for stone manipulation. These findings support in vivo trials of the software to enhance clinical decisionmaking in ureteroscopic stone management. With increasing rates of renal failure and limited options for its treatment, there is an urgent need of implementing our knowledge and resources to guide new strategies for understanding disease-and patient-specific glomerular pathophysiology and for developing more efficient drug screening tools. Recreating an ex-vivo functional glomerulus depends on our ability to generate an in vitro 3D multicellular system that allows fluid perfusion and proper interactions between podocytes and glomerular endothelial cells (hGEC) in a platform that mimics the complex architecture of the glomerular filtration barrier (GFB).
METHODS: Amniotic fluid derived podocytes (hAKPC-P), human immortalized podocytes (hiPod), primary human podocytes (hpPod) and human fibroblasts or human lung endothelial cells (negative controls) were seeded on microfluidic chips with hGEC. Immunofluorescence was performed for podocyte, endothelial and GBM markers. Barrier selectivepermeability was investigated. Feasibility of the system for high throughput screening was evaluated by measuring permselectivity following Puromycin Aminonucleoside (PAN) injury or culture with serum membranous nephropathy (MN) patients. Drug screening for MN and disease modeling for Alport Syndrome (AS) were also performed. RESULTS: We have developed an innovative, barrier-free, glomerulus-on-a-chip (GOAC) system. Podocytes formed a slit diaphragm-like structure expressing nephrin. CD31-expressing hGEC formed capillary-like structures. De-novo deposition of GBM components such as collagen IV and laminin alpha5 was verified. Albumin permselectivity was confirmed and permselectivity was impaired following PAN administration as confirmed by our assay. In the presence of MN serum the chip displayed IgG deposition on the podocytes and loss of permselectivity to albumin, to an extent proportional to urinary protein loss in vivo. ACTH successfully rescued MN-mediated damage, confirming feasibility for drug screening. Chip structure and function were impaired when we used podocytes from individuals with AS, a kidney disease due to genetically determined collagen abnormalities.
CONCLUSIONS: We have successfully developed a GOAC system that closely mimics the GFB structure and provides a powerful tool for studying renal regenerative and disease mechanisms, toxicity effects and will help the discovery of new drugs. In conclusion, this system will increase our ability to individualize treatments and drug susceptibility, thus ultimately benefiting patients affected by renal failure.
